Nichols Institute
This article was originally published in The Gray Sheet
Executive Summary
Files registration statement with the Securities and Exchange Commission related to a planned offering of $100 mil. of senior debt notes due 2001. Out of estimated net proceeds of $96 mil., about $69.7 mil. would go toward repayment of various existing debts, approximately $5.5 mil. would go toward redemption and payment of accrued dividends on Series E convertible preferred stock, approximately $10 mil. would fund a 1994 capital expenditures program, and $10.8 mil. would go toward general corporate purposes. The refinancing is expected to "improve significantly [the firm's] operating and financial flexibility," the filing states. In 1993, the clinical lab testing company had revenues of $279.6 mil. and a net loss of $4.4 mil
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.